Depression and survival of glioma patients: A systematic review and meta-analysis
Highlights
- •
There is currently a lack of information regarding the influence of depression on the survival of glioma patients.
- •
Results from six studies were pooled to examine the correlation between depression and survival in glioma patients.
- •
Depression was associated with significantly worse survival outcomes, especially among patients with high-grade glioma.
- •
This correlation was not influenced by depression timing (i.e. pre- vs. post-operative).
Abstract
Introduction
There is currently a lack of a well-formed consensus regarding the effects of depression on the survival of glioma patients. A more thorough understanding of such effects may better highlight the importance of recognizing depressive symptoms in this patient population and guide treatment plans in the future.
Objective
The aim of this meta-analysis was to study the effect of depression on glioma patients’ survival.
Methods
A meta-analysis was conducted according to the PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for studies that reported depression and survival among glioma patients through 11/06/2016. Both random-effects (RE) and fixed-effect (FE) models were used to compare survival outcomes in glioma patients with and without depression.
Results
Out of 619 identified articles, six were selected for the meta-analysis. Using RE model, the various measures for survival outcomes displayed worsened outcomes for both high and low-grade glioma patients with depression compared to those without depression. For binary survival outcomes, the overall pooled risk ratio for survival was 0.70 (95% CI: 0.47, 1.04; 6 studies; I2 = 54.9%, P-heterogeneity = 0.05) for high grade gliomas (HGG) and 0.28 (95% CI: 0.04, 1.78; I2 = 0%, P-heterogeneity = 1.00; one study) for low grade gliomas (LGG) was. A sub-group analysis in the HGG group by depression timing (pre- versus post-operative) revealed no differences between depression and survival outcomes (P-interaction = 0.47). For continuous survival outcomes, no statistically significant difference was found among the high and low-grade glioma groups (P-interaction = 0.31). The standardized mean difference (SMD) in survival outcomes was −0.56 months (95%CI: −1.13, 0.02; 4 studies, I2 = 89.4%, P-heterogeneity < 0.01) for HGG and −1.69 months (95%CI: −3.26, −0.13; one study; I2 = 0%, P-heterogeneity = 1.00) for LGG. In patients with HGG, the pooled HR of death also showed a borderline significant increased risk of death among depressive patients (HR 1.42, 95% CI: 1.00, 2.01). Results using the FE model were not materially different.
Conclusions
Depression was associated with significantly worsened survival regardless of time of diagnosis, especially among patients with high-grade glioma.